PANAMA CITY, Dec. 9, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, today announced integration with Trade4Me to provide users direct access to a range of institutional-grade automated trading strategies. This collaboration introduces advanced, risk-controlled algorithmic trading to BingX users starting from 1,000 USDC.

Trade4Me develops automated trading systems designed to operate with precision in highly liquid digital asset markets. The company specializes in quantitative strategies that apply multi-layered risk controls, live monitoring, and high-frequency decision models to capture opportunities in BTC and ETH markets while mitigating volatility exposure. Trade4Me’s strategies detect and act on small-scale trend movements in BTC and ETH through frequent micro-profit trades.

Vivien Lin, Chief Product Officer at BingX, commented: “BingX aims to give retail traders fair access to the same caliber of tools used by institutional investors. Partnering with Trade4Me allows us to offer fully automated, professionally engineered trading strategies with a clear risk-management framework. This integration supports our goal of expanding high-quality trading solutions on BingX and enabling users to participate with confidence.”

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information, please visit: https://bingx.com/

NEW YORK, Dec. 9, 2025 /PRNewswire/ — Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical’s most influential international sub-brands, Dimora Medical played a pivotal role in this achievement, driven by its industry-leading performance in Amazon’s wound-care category.

“Several years ago, as we watched the advanced wound care market surge in Europe and North America, it became clear that high-performance dressings had room to grow beyond hospital use,” said Yan Zhang, Marketing VP at Dimora Medical. “The market was worth billions, yet the Amazon category was still tiny. It was a clear blue-ocean opportunity to reimagine clinical products for everyday home-care needs.”

Early in its Amazon launch, despite the advantage of in-house product development and manufacturing, sales grew gradually. The turning point came with a fundamental insight: home users required solutions tailored to everyday care, not hospital routines.

This insight prompted a series of strategic products and brand adjustments. The company introduced micro-innovations for household use, adding multiple sizes for everyday wound care and developing contoured dressings for joint areas where standard formats fail to adhere. Packaging was also redesigned with smaller, more refined boxes suited to household routines.

Dimora Medical also defined four core home-care scenarios: pressure-injury prevention for bedridden seniors, post-surgical recovery at home, children’s minor wounds, and injuries related to outdoor activities. Visual storytelling through its flagship store and enhanced content pages helped consumers intuitively understand how to use the products and which situations they were designed for.

As reviews grew, the brand identified an unexpected yet influential user group: family physicians who turned to Amazon to source dressings for patient care. Their professional feedback informed listing improvements and strengthened brand credibility. Consistent quality and scenario-driven marketing helped Dimora Medical’s foam dressings emerge as a breakout success, driving rising institutional demand. Enterprise purchasing has maintained strong double-digit growth, contributing significantly to Dimora Medical’s cross-border expansion and reinforcing its leadership in Amazon’s rapidly growing wound-care category.

Dimora Medical looks forward to deepening collaborations with global partners, strengthening its role in shaping the future of accessible, high-quality wound care, and welcoming new distributors and stakeholders interested in joining its expanding global ecosystem.

For more information, please visit: https://dimoramedical.com/.

HONG KONG, Dec. 9, 2025 /PRNewswire/ — The recent tragic fire at Tai Po has brought sadness and loss to our community. The seven Zonta Clubs in Hong Kong would like to express our deepest condolences to the victims and to extend our sympathy to all those affected. The swift response from all sectors of society reflects Hong Kong’s spirit of helping each other during tough times, while also reminding us of the needs of vulnerable groups.

According to the World Health Organization (WHO), violence against women and girls remains the most widespread and pervasive human rights violation globally, affecting an estimated one in three women—a figure that has remained largely unchanged over the past decade. This violence knows no national or cultural barriers; it occurs at home, in the workplace, and in public spaces, impacting millions of women and girls in both peacetime and conflict. The COVID-19 pandemic intensified violence against women, with a 2022 study revealing that nearly 40% of women in Hong Kong have experienced sexual abuse. The WHO estimates the actual figures are likely higher.

Zonta International has long been unwavering in its advocacy to end violence against women. Since launching the “Zonta Says NO to Violence Against Women” campaign in 2012, it has held its annual “16 Days of Activism” between November and December, uniting Zonta Clubs worldwide in impactful advocacy actions to combat violence against women and girls. As members of Zonta International, Zonta Clubs in Hong Kong have responded actively to this call.

Recently (8 December), seven Zonta Clubs in Hong Kong — Zonta Club of Hong Kong, Zonta Club of Kowloon, Zonta Club of Hong Kong East, Zonta Club of The New Territories, Zonta Club of Victoria Hong Kong, Zonta Club of Hong Kong II, and Zonta Club of The New Territories II— joined forces to support the Po Leung Kuk’s mobile  art exhibition “Violence? Love!!: A Voyage of Discovery”, which aims to educate the community about domestic violence and related family crisis support services.  This event is a key part of this year’s “16 Days of Activism” under the “Zonta Says NO to Violence Against Women” campaign.

The launch of the mobile art exhibition was witnessed by Zonta International District 17 Governor Mrs Winnie Wong, Zonta International District 17 Area 2 Director Ms Thelma Tong, presidents of the seven Zonta Clubs in Hong Kong, and the Chairman of Po Leung Kuk Ms Amanda Ho, JP.

Zonta International District 17 Governor Mrs Winnie Wong said: “Today, Zonta International and the seven Zonta Clubs in Hong Kong are delighted to support the Po Leung Kuk’s ‘Violence? Love!!: A Voyage of Discovery’ mobile art exhibition, which aims to raise public awareness about domestic violence.  Zonta is committed to advancing the status of women through service and advocacy. The annual ‘Zonta Says NO to Violence Against Women’ campaign and its ’16 Days of Activism’, which begins on the United Nation’s (UN) International Day for the Elimination of Violence Against Women on 25 November and concludes on the UN’s International Human Rights Day on 10 December, are aligned with the UN’s call to mobilise all sectors of society in support of gender equality and women’s rights.”

Chairman of Po Leung Kuk Ms Amanda Ho, JP, explained that through the voices and stories of victims of domestic abuse, the exhibition highlights that domestic violence often lies hidden within everyday life. The courage and transformation of every survivor deserves to be heard and supported by everyone. Through the exhibition, which also highlights the Po Leung Kuk’s support services, the Po Leung Kuk not only walks alongside affected families but also aims to show how to build healthier and happier families.

The “Violence? Love!!: A Voyage of Discovery” mobile art exhibition vehicle will tour Hong Kong Island, Kowloon and the New Territories from 8 to 14 December, including stops in Causeway Bay, Wan Chai, Mong Kok, Wong Tai Sin, Tai Wai and Tsuen Wan. Entry is free of charge.

The exhibition features interactive experience zones, allowing visitors to understand the reality of domestic violence and the possibility of transforming “violence” into “love”.  This includes “The True Stories of Seven Weapons”, which through activities and personal stories inspires visitors to build positive family relationships.

About Zonta Clubs in Hong Kong
All Zonta Clubs in Hong Kong are non-profit organisations under Zonta International (www.zonta.org), founded in the USA in 1919. Zonta International is a global service organisation of professionals and executives working together to advance the status of women through community service and advocacy. Zonta International members are spread across more than 65 countries and regions worldwide, working at international, national and local levels to achieve the organisation’s vision: committed to building women’s rights, enabling every woman to fully realise her potential, and creating a better world for women. Currently, there are eight Zonta Clubs in Hong Kong: Zonta Club of Hong Kong, Zonta Club of Kowloon, Zonta Club of Hong Kong East, Zonta Club of The New Territories, Zonta Club of Victoria Hong Kong, Zonta Club of Hong Kong II, Zonta Club of The New Territories II, and Zonta Club of Kowloon II.

Appendix

“Violence? Love!!: A Voyage of Discovery” Mobile Art Exhibition Tour Details

Dates:  8 to 14 December 2025

Schedule/Venue:

Organiser: Po Leung Kuk

Supporting Organisations: 

Seven Zonta Clubs in Hong Kong, including: Zonta Club of Hong Kong, Zonta Club of Kowloon, Zonta Club of Hong Kong East, Zonta Club of The New Territories, Zonta Club of Victoria Hong Kong, Zonta Club of Hong Kong II, and Zonta Club of The New Territories II.

For media enquiry: ZontaVicHK@gmail.com 

DUBAI, UAE, Dec. 9, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is pleased to announce Boost Battle, a new competitive trading fiesta designed for wealth builders. Top-performing participants stand to win up to 10,000 USDT weekly, with competitions resetting each week.

Starting now until February 1, 2026, Boost Battle features eight weekly rounds where traders compete for prizes based on their trading volume. Each week, the highest ranking trader by accumulated points will win the grand prize of 10,000 USDT. To accept the challenge, eligible users may register now for the event and simply start trading to accumulate points. No complicated rules, no extra requirements – just trading.

How it works:

• Trading non-zero-fee pairs on Bybit Spot or Futures to accumulate points based on weekly trading volume
• In each round, registered participants can find the week’s featured “boosted tokens” on the event page for extra points
• Competing for the top position on the weekly leaderboard

Bonus Opportunity:

• Traders who achieve 10,000 USDT in daily trading volume on Spot or Futures will receive Lucky Draw tickets for additional prizes

Boost Battle is part of Bybit’s ongoing commitment to empowering traders at every experience level. By rewarding consistent trading activity and turning portfolio management into competitive opportunities, the event helps participants build momentum in their journey toward financial goals while making every trade count.

Restrictions apply. Full terms and conditions are available at: Boost Battle: Trade daily and win up to 10,000 USDT every week!

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press 

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

In the news release, Empyrion Digital Unveils Johor’s Newest Large-scale Next-Generation Hyperscale Data Centre Campus, issued 08-Dec-2025 by Empyrion Digital over PR Newswire, we are advised by the company that the second paragraph, 1st sentence, should read “Malaysia’s recent tightening of approvals” rather than “Malaysia’s national data centre moratorium” as originally issued inadvertently; The second bullet point should read “One of Johor’s rare, approved DC sites”. The complete, corrected release follows:

Empyrion Digital Unveils Johor’s Newest Large-scale Next-Generation Hyperscale Data Centre Campus

• 200+MW hyperscale campus with five 40MW buildings
• One of Johor’s rare, approved DC sites
• Earliest energisation from Sep 2026; first phase targeted RFS in Q4 2026

SINGAPORE, Dec. 9, 2025 /PRNewswire/ — Empyrion Digital, a Singapore-headquartered next-generation data centre developer and operator, today announced regulatory approval for both the Electricity Supply Agreement (ESA) and Data Centre Task Force (DCTF) application for its first data centre campus in Malaysia. Located in Nusajaya within the SiLC Industrial Cluster of Johor, the project represents Empyrion Digital’s largest investment to date and its sixth data centre development across Asia.

The Johor Data Centre Campus (“MY1”) will be developed on a rare 34.9-acre site, making it one of the few projects in the country to secure both site approval and power allocation despite Malaysia’s recent tightening of approvals. This strategic milestone underscores the importance of MY1 not only to Johor’s digital infrastructure roadmap but also to the region’s accelerating AI and cloud computing ecosystem.

Designed as a 200+MW next generation hyperscale campus, MY1 will comprise five 40MW buildings developed in phases to meet surging demand for high-performance computing, artificial intelligence (AI), and cloud infrastructure in Southeast Asia. The first phase is targeted to be Ready-for-Service (RFS) in Q4 2026.

Empyrion Digital has secured 145MW of initial power allocation from Tenaga Nasional Berhad (TNB), with earliest energisation targeted for September 2026, and scalability to support the full campus. TNB will supply a stable, high-capacity electricity feed for hyperscale workloads.

MY1 will incorporate state-of-the-art liquid and air-cooled technologies, targeting a PUE below 1.3 for liquid cooling and below 1.4 for air cooling. The campus will also have access to green energy through long-term PPAs, in line with Empyrion Digital’s commitment to efficient and responsible operations.

Strengthening Cross-Border Connectivity Between Johor and Singapore

Beyond hyperscale capacity, MY1 will play a critical regional role in enhancing cross-border digital connectivity between Johor and Singapore. Through Empyrion’s sister connectivity platform, SPTel under Seraya Partners’ AQX Digital Infrastructure, customers will gain future access to secure, diverse, and low-latency routes linking MY1 in Johor to Empyrion’s SG1 data centre in Singapore.

These routes will significantly improve network diversity, operational resilience, and digital sovereignty, enabling customers to deploy multi-site AI, hybrid cloud, and disaster recovery architectures across the two locations. MY1 will therefore serve not only as a key hyperscale hub but also as a strategic extension of Singapore’s digital ecosystem.

Ernest Lee, Acting CEO of SPTel, said:
“We see strong potential in collaborating with Empyrion to integrate resilient connectivity and edge cloud capabilities across Singapore and Johor. By combining SPTel’s secure, software-defined network with Empyrion’s data centre footprint, we aim to deliver faster, more flexible digital infrastructure solutions for customers in the region.”

Mark Fong, CEO of Empyrion Digital, said:
“Malaysia has emerged as a key destination for hyperscale data centres, driven by strong digital transformation, favourable infrastructure, and government support. MY1 reflects Empyrion Digital’s continued ambition to expand our pan-Asian platform and meet our customers’ needs for scalable, green-by-design, and AI-ready infrastructure. Johor will be a cornerstone location in this strategy.”

Once completed, MY1 will join Empyrion Digital’s growing regional platform, which includes operational and development projects in Singapore, Seoul, Tokyo, Taipei, and Bangkok, bringing the company’s total IT capacity across Asia to well over 200MW.

About Empyrion Digital
Empyrion Digital is a next-generation digital infrastructure platform committed to sustainable practices and operational excellence. Green-by-design, we develop and operate scalable, carrier-neutral data centres for hyperscale and enterprise customers across Asia.

Headquartered in Singapore, Empyrion Digital is a portfolio company of Seraya Partners, a leading Asia infrastructure fund with USD 2.2 billion of assets under management as of 30 Sep 2025.

For more information, visit www.empyriondigital.com

VICTORIA, Seychelles, Dec. 9, 2025 /PRNewswire/ — MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true zero-fee trading, has published its latest independent Proof of Reserves (PoR) report conducted by blockchain security and audit firm Hacken. MEXC continues to safeguard core assets while providing a fully auditable view of user balances, reinforcing our unwavering commitment to 100% fully backed user fund safety. The report, completed on November 26, 2025, confirms that MEXC holds sufficient on-chain assets to fully cover all user liabilities, with coverage ratios for major assets — including BTC, ETH, USDT, and USDC — consistently exceeding 100%.

According to the audit, Hacken conducted a comprehensive evaluation of MEXC’s reserves using industry-standard methodologies, including Proof of Liabilities, Proof of Ownership, reserve sufficiency calculations, and Merkle-tree verification. MEXC’s Proof of Reserves framework aggregates anonymized user balances and maps them to publicly verifiable on-chain holdings, enabling independent validation of solvency without compromising personal information. The auditor verified that MEXC maintains operational control over all wallets included in the assessment and confirmed that user balances are fully backed based on the assets reviewed.

The examination covered a broad range of networks, with reserve wallets identified across Bitcoin, Ethereum, Solana, TON, Tron, BNB Chain, Arbitrum, Optimism, Avalanche-C, Base, Polygon, Aptos and Sui. The report also provides detailed breakdowns of wallet addresses, balances, and asset distribution. The final reserve ratio table confirms that each major asset class is supported by reserves exceeding its liabilities.

Hacken reviewed outbound transactions from selected addresses as part of its Proof of Ownership procedures and validated the integrity of the Merkle-tree structure used to compute user liabilities. These transparency efforts are underpinned by MEXC’s continuously refreshed Proof of Reserves framework and an independently maintained protection system, giving users and counterparties verified confirmation of reserve coverage, strict asset segregation, and real-time fund accessibility.

“At MEXC, we are fully committed to transparency and security, and this report once again demonstrates our unwavering dedication to 100% user fund safety,” said Vugar Usi, COO of MEXC. “Independent Proof of Reserves audits are now a continuous, core standard practice within our operational framework. We will continue working with established auditing firms such as Hacken to ensure our users have verifiable assurance that their assets are fully backed.”

Hacken concludes that MEXC’s reserve structure demonstrates full solvency, including the accounting of off-exchange obligations. The report highlights the proper implementation of the PoR methodology, the quality of the supplied data, diversified asset holdings, and the exchange’s high level of responsibility toward its users.

“We’ve seen increased transparency demand in the crypto industry over the past year, and the results of MEXC’s audit reflect this shift”, noted a spokesperson for Hacken. “Our audit confirmed that the exchange has sufficient asset reserves and a clear reserve management structure. In an environment where trust is built only through verifiable data, MEXC demonstrates its willingness to operate transparently and back up its commitments with facts, not words”.

Hacken also emphasizes that the results serve as a “testament to the responsible financial management practices employed by MEXC, as well as the company’s dedication to transparency and accountability”.

Regular Proof of Reserves audits remain central to MEXC’s long-term strategy to strengthen trust and elevate industry standards. As global demand for accountability and compliance in cryptocurrency trading grows, verified reserve transparency has become essential to build user confidence and demonstrate real financial resilience. The release of the latest independent audit by Hacken powerfully reinforces MEXC’s standing as a global benchmark for trust, transparency, and resilience—setting a gold standard for accountability in the worldwide crypto ecosystem.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

About Hacken

Hacken is a trusted blockchain security auditor on a mission to make Web3 a safer place. With a team of 60+ certified engineers, it provides solutions covering all aspects of blockchain security, such as smart contract & protocol audits, bug bounties, and security assessments. Hacken has been raising the bar for blockchain security, working with more than 1,500 Web3 projects since its inception in 2017.
For more information, visit: Hacken Website｜X｜LinkedIn

SHANGHAI, Dec. 9, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma.

Golidocitinib

• Newly diagnosed PTCL

Two dose regimes of golidocitinib combined with CHOP have been explored for the treatment of newly diagnosed PTCL. Both demonstrated promising antitumor activities and a manageable safety profiles.

• • Golidocitinib 75mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 94.1% and a CR rate of 64.7%. By the data cutoff date, 85% of patients remained on treatment.
  • Golidocitinib 150mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 88.9% and a CR rate of 61.1%
     
• R/R PTCL

An updated 2-year follow-up from the MD Anderson Cancer Center cohort of the multinational pivotal trial JACKPOT8 Part B showed that golidocitinib monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) achieved an objective response rate (ORR) of 53.8% and a complete response (CR) rate of 46.1%. Median progression-free survival (PFS) was 37.9 months and the 2-year PFS rate was 58.3%. The research findings validated golidocitinib’s long-lasting efficacy and tolerability in the U.S. patient population.

• Rare subtypes of PTCL

Golidocitinib monotherapy demonstrated compelling clinical activity with a favorable safety profile in heavily pretreated relapsed or refractory T-cell and NK-cell large granular lymphocyte leukemia (r/r T-LGLL) patients. Results from a prospective study showed an ORR of 92.3% and a CR rate of 61.15%. Additionally, the study reported a 100% response among STAT3-wildtype patients.

A Phase II clinical study showed that golidocitinib in combination with CHOP demonstrated profound antitumor activity in treatment-naïve monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). The ORR was 85.7% and the CR rate was 71.4%, demonstrating a significant therapeutic advance over conventional chemotherapy.

• PTCL-associated HLH

In r/r PTCL-associated hemophagocytic lymphohistiocytosis (HLH), golidocitinib-based regimens demonstrated dual anti-HLH and antitumor efficacy, with rapid clinical improvement and an ORR of 46.7%. Most patients achieved systemic and hematologic recovery with a manageable safety profile. These findings highlight the potential of JAK1 inhibition in this high-risk disease.

Birelentinib

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a malignancy originating from mature B-cell non-Hodgkin lymphoma (B-NHL). While Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of B-cell lymphomas, resistance remains a significant challenge. Two primary types of resistance mutations have been identified after BTK inhibitor treatment for B-NHL: BTK-dependent and non-BTK pathway-mediated resistance. Although the BTK-dependent resistance is well-characterized, the emergence of kinase-impaired BTK mutations underscores the increasingly recognized role of non-BTK pathways.

Birelentinib is designed to block both BTK-dependent and BTK independent BCR signaling. Building upon promising data presented orally at the 2025 ASCO Annual Meeting and the 18th International Conference on Malignant Lymphoma (ICML), updated follow-up data of birelentinib reported at this ASH Annual Meeting demonstrated potent anti-tumor efficacy with a manageable safety profile in heavily pre-treated CLL/SLL patients.

At 50 mg QD (RP3D), birelentinib achieved an ORR of 84.2%. Tumor responses were observed irrespective of prior BTK inhibitor, BCL-2 inhibitor or BTK degrader treatment, and in patients with kinase-proficient or kinase-impaired BTK mutation. Antitumor efficacy proved durable, with no new safety concerns identified during follow-up.

Based on the encouraging results, birelentinib has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). The global multicenter Phase III study in r/r CLL/SLL is currently ongoing.

About Golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About Birelentinib (DZD8586)

Two resistance mechanisms have been found in patients whose diseases have progressed on a BTK inhibitor treatment: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed to treat both BTK-dependent and BTK-independent B-cell non-Hodgkin lymphoma (B-NHL).

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio. ZEGFROVY is the first and only small molecule drug approved in both the U.S. and China, for the treatment of non-small cell lung cancer with EGFR exon20 insertion mutations. Golidocitinib has been approved in China for the treatment of relapsed and refractory PTCL. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com